Could a common diabetes pill unstiffen aging arteries?

NCT ID NCT06506422

Recruiting now Disease control Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether empagliflozin, a drug currently used for diabetes, can reverse the natural stiffening of arteries that happens with age. Researchers will give 80 healthy adults aged 60-80 either the drug or a placebo daily for 12 weeks. The main goal is to see if artery stiffness, measured by a standard test, improves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (a diabetes drug, here tested for artery health)
What this could lead to: If it works, this could point toward a simple daily pill to reduce artery stiffness and potentially lower heart risks in older adults.
What could go wrong: This is an early-phase study with only 80 people, so results may not apply widely. The drug is already used for diabetes, but its effect on artery stiffness in non-diabetic people is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING ARTERIAL STIFFNESS

Contacts and locations

Locations

University of Missouri
RECRUITING

Columbia, Missouri, 65211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.